Abstract
Background:
Nowadays, the use of over-the-counter drugs such as acetaminophen (APAP) may cause severe liver injury, which can occur not only in high doses but also in therapeutic doses due to nutritional deficiency, alcoholism, or using cytochrome p450 inducers.Objectives:
In this study, the protective effect of epicatechin (EPC) was evaluated against APAP-induced hepatotoxicity to find an effective and inexpensive therapy.Methods:
The animals were divided into preventive and therapeutic groups. In the preventive study, the animals received EPC (25, 50, and 100 mg/kg/day) for five days, and the last dose was administered 1 hour before APAP (400 mg/kg). In the therapeutic groups, the animals received EPC just before and 2 hours after the APAP injection. All the animals were killed, and blood and liver samples were taken for further analysis. The liver pathology, enzymes, and oxidant, antioxidant, inflammatory, and anti-inflammatory factors were evaluated.Results:
EPC significantly decreased the serum activity level of the liver biomarkers ALT and AST in the APAP-treated mice. Furthermore, the hepatic levels of thiobarbituric acid-reactive substances were noticeably lowered, and the levels of total thiol and catalase activity increased significantly with EPC. Histopathological results were strongly consistent with those of the biochemical estimations. The most effective dose was observed at EPC 100 mg/kg, and the therapeutic groups showed better results than the preventive groups.Conclusions:
EPC attenuated the liver toxicity in the mice by suppressing oxidative stress and can be considered a preventive and therapeutic agent for inhibiting and resolving the liver damage induced by APAP.Keywords
Acetaminophen Hepatotoxicity Oxidative Stress Epicatechin Preventive Therapeutic
1. Background
Acetaminophen (APAP) is a very safe over-the-counter (OTC) analgesic and antipyretic agent. However, intoxication from overdosing or the chronic use of APAP, nutritional deficiency, alcoholism, malabsorption syndromes, and CYP2E1 inducers may cause liver injury, which is characterized by elevated serum aminotransferases, hemorrhage, and central lobular necrosis, leading to death in a complicated situation (1, 2).
APAP hepatotoxicity begins with the metabolism of the N-acetyl-p benzoquinone imine (NAPQI) by cytochrome P (CYP)-450, which is very reactive. NAPQI depletes glutathione (GSH) and binds to proteins. Moreover, it causes oxidative stress and mitochondrial dysfunction (3, 4). However, the liver can regenerate hepatocytes. Due to the slow rate of regeneration, liver protectants such as antioxidants play an essential role in increasing survival rates by fighting against free radical species (5, 6).
Recently, evaluating the protective potentials of plants and phytochemicals has attracted much attention due to their natural origin, lower cost, higher effectiveness, and fewer side effects. These components can range in molecular weight from monomers to long-chain polymers (7, 8). Epicatechin (EPC) is one of the most potent antioxidants existing in the human diet and can be found predominantly in grapes, tea, apples, and cocoa (9). EPC is a significant member of the flavanol family with biological activities, including preventing LDL oxidation (10, 11), scavenging reactive oxygen species (ROS) (12), and anti-inflammatory activity (13).
Epidemiologic and animal studies have shown that EPC has beneficial health effects on cancer (14), inflammation, and diabetes (15, 16). In addition, EPC decreases infarct size and blood pressure (17). EPC has direct and indirect antioxidant properties. A direct antioxidant effect includes scavenging free radicals and chelating redox-active metals (18, 19). However, indirect antioxidant effects of EPC include modulating the NADPH oxidase (20), inhibiting the binding of tumor necrosis factor (TNF-α) to its receptor (15), interfering with NF-κB activation (21), and activating Nrf2 (22, 23). Moreover, EPC has a beneficial effect on reducing the steroid-induced fatty liver by activating AMPK, which increases fat oxidation and prevents hepatic steatosis (24).
2. Objectives
The present study aimed to evaluate the preventive and therapeutic effects of EPC against APAP-induced liver injury.
3. Methods
3.1. Chemicals
Epicatechin, thiobarbituric acid, trichloroacetic acid, and 5,5′-dithiobis (2-nitrobenzoic acid) were purchased from Sigma Aldrich. Ammonium molybdate, hydrogen peroxide (H2O2), APAP, and ethylenediaminetetraacetic acid (EDTA) were also obtained from Sigma Aldrich.
3.2. Animals and Ethical Statements
All animal experiments were approved by the Institutional Animal Care and Use Committee of Ahvaz Jundishapur University of Medical Sciences (AJUMS). Male BALB/c mice aged six to eight weeks, weighing around 25±2 g, were used. Mice were housed under a controlled light (6 AM)/dark (6 PM) cycle at 25 ± 2ºC and given free access to rodent chow and acidified (tap) water until experimentation. The animal studies were approved by the ethical committee of the AJUMS with the approval of code IR.AJUMS.REC.1394.730.
3.3. Experimental Design
This study was conducted using seven preventive and seven therapeutic groups to evaluate the effect of EPC on APAP-induced hepatotoxicity. The groups of six mice received intraperitoneal injections of saline, EPC, and APAP.
Group 1: Saline (10 mL/kg)
Group 2: EPC (100 mg/kg) + saline (10 mL/kg)
Group 3: Saline + APAP 400 mg/kg
Groups 4, 5, 6: EPC (25, 50, 100 mg/kg) + APAP 400 mg/kg
Group 7: N-acetyl cysteine (NAC) 50 mg/kg + APAP 400 mg/kg
In therapeutic groups, animals received EPC just before and 2 hours after the APAP injection. After receiving an APAP injection and fasting overnight, all animals were sacrificed under anesthesia. The serum was obtained through centrifugation of the blood collected via cardiac puncture at a rate of 3000×g 15 min. The liver was rapidly removed for histopathologic examination and measurement of total thiol (TT), TBARS (thiobarbituric acid reactive substances), and catalase activity (CAT). The level of protection was assessed utilizing biochemical markers, namely serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
3.4. Determination of Liver Markers in Serum
The activity of ALT and AST was determined according to the protocols provided with the commercial kits (Pars Azmoon Company).
3.5. Determination of Thiobarbituric Acid Reactive Substances
A standard protocol was used to estimate TBARS in homogenate liver samples (25). Briefly, the supernatant of liver samples was incubated with thiobarbituric acid at 95°C for 10 min, and the absorbance of the supernatant was measured at 532 nm. The amount of lipid peroxidation was determined using ɛ = 1.56 × 105 /M/cm and expressed as nmol/g tissue.
3.6. Determination of Total Thiol
Total thiol was determined according to the method reported by Ellman’s method (26). Liver supernatants were incubated with Ellman’s reagent, and the absorbance of the yellow-colored complex was read at 412 nm. The result was expressed as µmole/g tissue.
3.7. Determination of Catalase Activity
Catalase activity was investigated according to the method used by Goth (27). The sample and H2O2 were mixed and incubated for 10 minutes before adding ammonium molybdate. At 410 nm, the absorbance was measured, and the result was expressed as U/g tissue.
3.8. Histopathological Examination
The livers of mice were fixed in a 10% formalin solution and subsequently embedded in paraffin. The specimens were sliced into sections measuring 5 µm and subsequently subjected to staining via hematoxylin and eosin (H&E).
3.9. Statistical Analysis
One-way analysis of variance (ANOVA) with Tukey's post-hoc was used for statistical evaluation of biochemical factors. For statistical analysis, the PRISM 9 software was used, and P < 0.05 was considered significant.
4. Results
4.1. Preventive and Therapeutic Effects of EPC on Hepatic Histopathology in Mice Model of APAP Hepatotoxicity
The representative histopathological examination of liver tissue is shown in Figure 1, and the descriptive histological scoring of liver damage is presented in Table 1. Liver sections showed normal hepatocytes in the saline group. Degeneration and coagulative necrosis in hepatocytes were observed in the APAP-treated group. Histopathological examination of the liver of the EPC (100 mg/kg)-treated mice in both preventive and therapeutic groups indicated similar results compared to their control groups. The histopathological analysis of the liver of mice co-treated with APAP and EPC resembled that of the control group in the therapeutic group. This indicates the protective effects of EPC in the APAP model of hepatotoxicity.
Preventive and therapeutic effects of epicatechin (EPC) and N-acetylcysteine (NAC) on APAP (acetaminophen)-induced hepatic histopathological injury in mice (n = 6 in each group). Preventive (A) and therapeutic (B) effects. Coagulative necrosis in hepatocytes (yellow arrow), fatty change in hepatocytes (red arrow), inflammatory cells (white arrow), and dilated sinusoids (black arrow). Saline, EPC 100 mg/kg (EPC100), APAP 400 mg/kg (APAP), EPC 25 mg/kg+ APAP 400 mg/kg (EPC25+ APAP), EPC 50 mg/kg + APAP 400 mg/kg (EPC50+APAP), EPC 100 mg/kg + APAP 400 mg/kg (EPC100+ APAP), NAC 50 mg/kg + APAP 400 mg/kg (NAC+APAP).
Preventive and Therapeutic Effects of Epicatechin (EPC) and N-acetylcysteine (NAC) on APAP (acetaminophen)-induced Hepatic Histopathological Injury in Mice (n = 6 in Each Group) a
| Preventive Groups | Saline | EPC 100 | APAP | EPC 25 + APAP | EPC 50 + APAP | EPC 100 + APAP | NAC + APAP |
|---|---|---|---|---|---|---|---|
| Semi-quantitative Scoring of Damage on Histopathological Examination of the Liver | |||||||
| Degeneration of hepatocytes | - | - | ++++ | +++ | +++ | + | + |
| Fatty change in hepatocytes | - | - | ++++ | +++ | ++++ | ++ | _ |
| Coagulative necrosis in hepatocytes | - | - | ++++ | ++++ | +++ | + | + |
| Infiltration of inflammatory cells | - | - | +++ | +++ | ++ | + | + |
| Dilated sinusoids | - | - | ++ | + | ++ | + | + |
| Therapeutic groups | Saline | EPC 100 | APAP | APAP+ EPC 25 | APAP+ EPC 50 | APAP+ EPC 100 | APAP+ NAC |
| Therapeutic Groups | |||||||
| Degeneration of hepatocytes | - | - | ++++ | ++ | + | - | +++ |
| Fatty change in hepatocytes | - | - | ++++ | ++ | + | + | ++ |
| Coagulative necrosis in hepatocytes | - | - | ++++ | + | + | - | + |
| Infiltration of inflammatory cells | - | - | +++ | + | + | + | + |
| Dilated sinusoids | - | - | ++ | - | ++ | - | _ |
Nonetheless, the liver sections in the group that received preventive treatment exhibited a lower degree of improvement compared to the control group. Compared to the APAP-treated group, the livers of the EPC- and NAC-treated groups exhibited a significant improvement in their histological structure, as indicated by a decrease in the severity of hepatic degeneration, fatty changes, infiltration of inflammation cells, coagulative necrosis, and dilation of sinusoids.
4.2. Preventive and Therapeutic Effects of EPC on Liver Function Enzymes in Mice Model of APAP Hepatotoxicity
EPC did not show significant alterations in the biochemical parameters compared to the control group, but APAP significantly elevated the ALT and AST levels. Even so, the administration of EPC to the treated groups decreased the serum levels of ALT and AST compared to the group treated with APAP. The results are shown in Figure 2.
Preventive and therapeutic effects of epicatechin (EPC) and N-acetylcysteine (NAC) on liver function enzymes in APAP (acetaminophen)-induced hepatic injury in mice (n = 6 in each group). The effect of EPC on serum ALT and AST activity is shown in the preventive groups (A and B) and therapeutic groups (C and D). Values are mean with their standard error of the mean (SEM). ANOVA Tukey's post-hoc was used for statistical analysis by PRISM 9 software. *Indicates significant difference from the APAP group (*P < 0.05). #Indicates a significant difference in the APAP group from the saline-treated group (# P < 0.05).
4.3. Preventive and Therapeutic Effects of EPC on TBARS Level in Mice Model of APAP Hepatotoxicity
The administration of APAP significantly elevated lipid peroxidation compared to the control group. Despite this, the administration of EPC in the therapeutic groups significantly reduced the elevation in the TBARS level. Co-administration of EPC in a preventive group significantly reduced TBARS levels, but to a lesser extent than in the therapeutic groups (Figure 3).
Preventive and therapeutic effects of epicatechin (EPC) and N-acetylcysteine (NAC) on hepatic content of TBARS and total thiol and CAT activity in APAP (acetaminophen)-induced oxidative stress in mice (n = 6 in each group). Effects of EPC on liver TBARS level in preventive (A) and therapeutic (B) groups, hepatic total thiol level in preventive (C) and therapeutic (D) groups, liver CAT activity in preventive (E) and therapeutic (F) groups. Values are mean with their standard error of the mean (SEM). ANOVA with Tukey's post-hoc was used for statistical analysis by PRISM 9 software. * Indicates significantly different from APAP group (*P < 0.05, ** P < 0.01, and *** P < 0.001). # Indicates a significant difference between the APAP group from saline and the treated group (#P < 0.05).
4.4. Preventive and Therapeutic Effects of EPC on Total Thiol Content in Mice Model of APAP Hepatotoxicity
The APAP-treated group showed a significant decrease in hepatic total thiol levels compared to the control group. Nonetheless, the administration of EPC to the treated rodents mitigated the reduction of total thiol. No significant statistical differences were observed between the control group and the EPC-received group in both therapeutic and preventive groups. The levels of total thiol are illustrated in Figure 3.
4.5. Preventive and Therapeutic Effects of EPC on Catalase Activity in Mice Model of APAP Hepatotoxicity
The activity of catalase (CAT) is shown in Figure 3. CAT activity in the liver was considerably lower in the APAP-treated groups compared to the saline-treated groups. IP injection of EPC (100 mg/kg) had no significant effect compared to the saline-treated group. The combined administration of APAP and EPC elevated CAT activity. The improvement in CAT activity of the therapeutic groups was greater than that of the preventive groups. EPC and NAC-treated groups showed a significant improvement in CAT activity compared to the APAP-treated groups.
5. Discussion
Severe liver injury is a current serious clinical problem that develops due to overdose or chronic use of APAP. Therefore, finding an effective and affordable therapy for liver injury is a critical priority for many researchers (28). The extent of hepatic damage is directly linked to the activity of ALT and AST enzymes in the serum, which are considered the most sensitive biomarkers (29). According to the results, administering APAP to the mice led to a significant rise in the activities of serum AST and ALT, indicating that the hepatocellular system was damaged. This elevation is attributable to the release of these enzymes from the cytoplasm into the bloodstream, which indicates necrosis or inflammatory responses (30, 31).
Oxidative damage is caused by the generation of reactive oxygen species, such as hydroxyl radicals and hydrogen peroxide, which interact with biological molecules, including proteins, lipids, and nucleic acids, leading to the impairment of membranes and other tissues. The TBARS assay has been employed as a suitable method for detecting oxidative damage (32). GSH is an essential antioxidant that assists detoxication by conjugating with NAPQI and preventing free radical damage (33). The significant increase in TBARS and a decrease in GSH in rodents treated with APAP can lead to the leakage of ALT and AST into the circulation due to liver damage.
Oxidative stress typically modifies the antioxidant status of a cell, which determines its susceptibility to oxidative injury. Moreover, hepatotoxicity can be a result of the liver's decreased antioxidant enzyme activity (34). Indeed, the antioxidant enzyme CAT restricts the action of oxidant molecules in tissues and acts as a free radical scavenger in the defense against oxidative cell damage (35). Our results indicated that APAP administration altered CAT activity in the livers of mice. These findings are consistent with prior research, which found that APAP exposure causes lipid peroxidation and changes the antioxidant state (36). This change could be due to decreased enzyme production or oxidative inactivation of enzymes.
The hepatoprotective efficacy of medicinal plants against APAP-induced hepatotoxicity is still under investigation. The current investigation found that EPC reversed the increase in lipid peroxidation. As a result, the mechanism of EPC hepatoprotection may be linked to polyphenolic chemicals, which scavenge a wide variety of free radicals, including the most active hydroxyl radical, which causes lipid peroxidation (37). It has previously been shown that phenolic substances chelate metal ions, particularly iron and copper, can inhibit the production of hydroxyl radicals and the degradation of lipid hydroperoxides (38).
In this study, the histological abnormalities can be described as degeneration, coagulative necrosis, fatty change, inflammation, and dilated sinusoids in APAP-treated groups, which were improved by EPC administration. The alleviation of inflammation in EPC-treated groups cannot be merely attributed to EPC antioxidant activity; it can also be due to its anti-inflammatory activity through inhibition of TNF-α and IL-1 (37). In a similar study, but with a different method, EPC ameliorated the inflammatory cytokines, histopathological changes, and apoptotic markers in the liver after administration of APAP (39). However, the preventive and therapeutic effects of EPC in routine doses have not been determined.
Antioxidant properties of EPC decreased lipid peroxidation and increased the antioxidant enzyme capacity in the liver, thereby repairing membrane damage and normalizing cell permeability (40, 41). According to our results, therapeutic groups had a better outcome than preventive groups, which emphasizes the importance of designing different study protocols. Based on these findings and the effects seen in other antioxidants like quercetin, hesperidin (42), diacerein (43), 6-shogaol (44), and others, more research is needed to find new compounds that can be used with acetaminophen to treat and prevent hepatotoxicity.
In conclusion, the current study found that APAP induced hepatotoxicity in mice. On the other hand, EPC decreased oxidative stress through its antioxidant capabilities, increased the structural integrity of the cell membrane, and subsequently alleviated histopathological and biochemical disturbances (Figure 4). Protective properties of EPC had the potential to mitigate APAP-induced hepatotoxicity by suppressing oxidative damage. One limitation of this research is that it investigated another mechanism and signaling pathway that EPC attenuates APAP hepatotoxicity. Based on our findings, it can be proposed that EPC can be used as an antioxidant for long-term therapeutic interventions against toxin-induced hepatotoxicity with minimal side effects.
The possible protective (preventive and therapeutic) effects of epicatechin against acetaminophen-induced liver toxicity.
Acknowledgements
References
-
1.
Wang J, Jiang W, Xin J, Xue W, Shi C, Wen J, et al. Caveolin-1 Alleviates Acetaminophen-Induced Fat Accumulation in Non-Alcoholic Fatty Liver Disease by Enhancing Hepatic Antioxidant Ability via Activating AMPK Pathway. Front Pharmacol. 2021;12:717276. [PubMed ID: 34305621]. [PubMed Central ID: PMC8293675]. https://doi.org/10.3389/fphar.2021.717276.
-
2.
Cai Y, Sun W, Zhang XX, Lin YD, Chen H, Li H. Osthole prevents acetaminophen-induced liver injury in mice. Acta Pharmacol Sin. 2018;39(1):74-84. [PubMed ID: 29022574]. [PubMed Central ID: PMC5758662]. https://doi.org/10.1038/aps.2017.129.
-
3.
Khodayar MJ, Kalantari H, Khorsandi L, Rashno M, Zeidooni L. Betaine protects mice against acetaminophen hepatotoxicity possibly via mitochondrial complex II and glutathione availability. Biomed Pharmacother. 2018;103:1436-45. [PubMed ID: 29864928]. https://doi.org/10.1016/j.biopha.2018.04.154.
-
4.
Jeong TB, Kim JH, Kim SH, Lee S, Son SW, Lim Y, et al. Comparison of toxic responses to acetaminophen challenge in ICR mice originating from different sources. Lab Anim Res. 2019;35:16. [PubMed ID: 32257904]. [PubMed Central ID: PMC7081583]. https://doi.org/10.1186/s42826-019-0017-x.
-
5.
Oliveira RP, Machado IF, Palmeira CM, Rolo AP. The potential role of sestrin 2 in liver regeneration. Free Radic Biol Med. 2021;163:255-67. [PubMed ID: 33359262]. https://doi.org/10.1016/j.freeradbiomed.2020.12.027.
-
6.
Chen L, Fan Z, Sun X, Qiu W, Mu W, Chai K, et al. Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study. Hepatol Int. 2023;17(2):326-38. [PubMed ID: 36352064]. https://doi.org/10.1007/s12072-022-10443-3.
-
7.
Srivastava P, Abul Kalam S. Natural Polymers as Potential Antiaging Constituents. Pharmacognosy. IntechOpen; 2019.
-
8.
Zafar F, Asif HM, Shaheen G, Ghauri AO, Rajpoot SR, Tasleem MW, et al. A comprehensive review on medicinal plants possessing antioxidant potential. Clin Exp Pharmacol Physiol. 2023;50(3):205-17. [PubMed ID: 36479862]. https://doi.org/10.1111/1440-1681.13743.
-
9.
Si H, Lai CQ, Liu D. Dietary Epicatechin, A Novel Anti-aging Bioactive Small Molecule. Curr Med Chem. 2021;28(1):3-18. [PubMed ID: 31886745]. https://doi.org/10.2174/0929867327666191230104958.
-
10.
Amoah I, Lim JJ, Osei EO, Arthur M, Cobbinah JC, Tawiah P. Effect of Cocoa Beverage and Dark Chocolate Intake on Lipid Profile in People Living with Normal and Elevated LDL Cholesterol: A Systematic Review and Meta-Analysis. Dietetics. 2023;2(3):215-36. https://doi.org/10.3390/dietetics2030017.
-
11.
Hid EJ, Mosele JI, Prince PD, Fraga CG, Galleano M. ( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action. Pflugers Arch. 2022;474(1):99-115. [PubMed ID: 34812946]. https://doi.org/10.1007/s00424-021-02640-0.
-
12.
Sadler DG, Barlow J, Draijer R, Jones H, Thijssen DHJ, Stewart CE. (-)-Epicatechin Alters Reactive Oxygen and Nitrogen Species Production Independent of Mitochondrial Respiration in Human Vascular Endothelial Cells. Oxid Med Cell Longev. 2022;2022:4413191. [PubMed ID: 35069974]. [PubMed Central ID: PMC8767396]. https://doi.org/10.1155/2022/4413191.
-
13.
Mani VM, Soundari A, Balasubramanian B, Park S, Issara U, Preethi K, et al. Evaluation of Dimer of Epicatechin from an Endophytic Fungus Curvularia australiensis FC2AP on Acute Toxicity Levels, Anti-Inflammatory and Anti-Cervical Cancer Activity in Animal Models. Molecules. 2021;26(3). [PubMed ID: 33513835]. [PubMed Central ID: PMC7866062]. https://doi.org/10.3390/molecules26030654.
-
14.
Sun W, Wong ILK, Law HK, Su X, Chan TCF, Sun G, et al. In Vivo Reversal of P-Glycoprotein-Mediated Drug Resistance in a Breast Cancer Xenograft and in Leukemia Models Using a Novel, Potent, and Nontoxic Epicatechin EC31. Int J Mol Sci. 2023;24(5). [PubMed ID: 36901808]. [PubMed Central ID: PMC10002220]. https://doi.org/10.3390/ijms24054377.
-
15.
Dash JR, Pattnaik G, Ghosh G, Rath G, Kar B. Protective effect of epicatechin in diabetic-induced peripheral neuropathy: A review. J Appl Pharm Sci. 2022. https://doi.org/10.7324/japs.2023.130105-1.
-
16.
Chen G, Cheng K, Niu Y, Zhu L, Wang X. (-)-Epicatechin gallate prevents inflammatory response in hypoxia-activated microglia and cerebral edema by inhibiting NF-kappaB signaling. Arch Biochem Biophys. 2022;729:109393. [PubMed ID: 36084697]. https://doi.org/10.1016/j.abb.2022.109393.
-
17.
Bustamante-Pozo M, Ramirez-Sanchez I, Garate-Carrillo A, Ito B, Navarrete V, Haro M, et al. (-)-Epicatechin Ameliorates Cardiac Fibrosis in a Female Rat Model of Pre-Heart Failure with Preserved Ejection Fraction. J Med Food. 2022;25(8):836-44. [PubMed ID: 35917528]. [PubMed Central ID: PMC9419952]. https://doi.org/10.1089/jmf.2021.0158.
-
18.
Galleano M, Verstraeten SV, Oteiza PI, Fraga CG. Antioxidant actions of flavonoids: thermodynamic and kinetic analysis. Arch Biochem Biophys. 2010;501(1):23-30. [PubMed ID: 20388486]. https://doi.org/10.1016/j.abb.2010.04.005.
-
19.
Zhang X, Li J, Li Y, Liu Z, Lin Y, Huang JA. Anti-melanogenic effects of epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG) and gallocatechin-3-gallate (GCG) via down-regulation of cAMP/CREB /MITF signaling pathway in B16F10 melanoma cells. Fitoterapia. 2020;145:104634. [PubMed ID: 32454171]. https://doi.org/10.1016/j.fitote.2020.104634.
-
20.
Cremonini E, Iglesias DE, Kang J, Lombardo GE, Mostofinejad Z, Wang Z, et al. (-)-Epicatechin and the comorbidities of obesity. Arch Biochem Biophys. 2020;690:108505. [PubMed ID: 32679195]. https://doi.org/10.1016/j.abb.2020.108505.
-
21.
Wu C, Li F, Zhang X, Xu W, Wang Y, Yao Y, et al. (-)-Epicatechin Ameliorates Monosodium Urate-Induced Acute Gouty Arthritis Through Inhibiting NLRP3 Inflammasome and the NF-kappaB Signaling Pathway. Front Pharmacol. 2022;13:799552. [PubMed ID: 35462936]. [PubMed Central ID: PMC9019746]. https://doi.org/10.3389/fphar.2022.799552.
-
22.
Huang Z, Jing X, Sheng Y, Zhang J, Hao Z, Wang Z, et al. (-)-Epicatechin attenuates hepatic sinusoidal obstruction syndrome by inhibiting liver oxidative and inflammatory injury. Redox Biol. 2019;22:101117. [PubMed ID: 30822691]. [PubMed Central ID: PMC6395886]. https://doi.org/10.1016/j.redox.2019.101117.
-
23.
Li Y, Ma S, Zhang Y, Yao M, Zhu X, Guan F. (-)-Epicatechin mitigates radiation-induced intestinal injury and promotes intestinal regeneration via suppressing oxidative stress. Free Radic Res. 2019;53(8):851-64. [PubMed ID: 31234659]. https://doi.org/10.1080/10715762.2019.1635692.
-
24.
Thomas J, Lanaspa MA, Schreiner G, Johnson RJ. Epicatechin Protects against Corticosteroid Induced Hepatic Steatosis. J Steroids Horm Sci. 2014;5(1). [PubMed ID: 34631239]. [PubMed Central ID: PMC8496346]. https://doi.org/10.4172/2157-7536.1000122.
-
25.
Sinha M, Manna P, Sil PC. Arjunolic acid attenuates arsenic-induced nephrotoxicity. Pathophysiology. 2008;15(3):147-56. [PubMed ID: 18434106]. https://doi.org/10.1016/j.pathophys.2008.03.001.
-
26.
Ellman GL. Reprint of: Tissue Sulfhydryl Groups. Arch Biochem Biophys. 2022;726:109245. [PubMed ID: 35667911]. https://doi.org/10.1016/j.abb.2022.109245.
-
27.
Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta. 1991;196(2-3):143-51. [PubMed ID: 2029780]. https://doi.org/10.1016/0009-8981(91)90067-m.
-
28.
Garcia-Cortes M, Ortega-Alonso A, Lucena MI, Andrade RJ, Spanish Group for the Study of Drug-Induced Liver Disease L. Drug-induced liver injury: a safety review. Expert Opin Drug Saf. 2018;17(8):795-804. [PubMed ID: 30059261]. https://doi.org/10.1080/14740338.2018.1505861.
-
29.
Andrade RJ, Robles-Diaz M. Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. Liver Int. 2020;40(1):6-17. [PubMed ID: 31578817]. https://doi.org/10.1111/liv.14271.
-
30.
Zhang C, Lin J, Zhen C, Wang F, Sun X, Kong X, et al. Amygdalin protects against acetaminophen-induced acute liver failure by reducing inflammatory response and inhibiting hepatocyte death. Biochem Biophys Res Commun. 2022;602:105-12. [PubMed ID: 35259588]. https://doi.org/10.1016/j.bbrc.2022.03.011.
-
31.
Adetuyi BO, Adebisi OA, Adetuyi OA, Ogunlana OO, Toloyai PE, Egbuna C, et al. Ficus exasperata Attenuates Acetaminophen-Induced Hepatic Damage via NF-kappaB Signaling Mechanism in Experimental Rat Model. Biomed Res Int. 2022;2022:6032511. [PubMed ID: 35655487]. [PubMed Central ID: PMC9155960]. https://doi.org/10.1155/2022/6032511.
-
32.
Ivanovic SR, Borozan N, Miladinovic DC, Zivkovic I, Borozan S. The relationship between the cholinergic mechanism of toxicity and oxidative stress in rats during subacute diazinon poisoning. Toxicol Appl Pharmacol. 2023;473:116598. [PubMed ID: 37331382]. https://doi.org/10.1016/j.taap.2023.116598.
-
33.
Park GC, Chung JW, Jang ES, Kim JW. Association between adverse outcomes of hepatitis A and acetaminophen use: A population-based cohort study. Dig Liver Dis. 2023;55(10):1368-74. [PubMed ID: 37088594]. https://doi.org/10.1016/j.dld.2023.03.017.
-
34.
Feng C, Bai H, Chang X, Wu Z, Dong W, Ma Q, et al. Aflatoxin B1-induced early developmental hepatotoxicity in larvae zebrafish. Chemosphere. 2023;340:139940. [PubMed ID: 37634582]. https://doi.org/10.1016/j.chemosphere.2023.139940.
-
35.
Cui Z, He F, Li X, Li Y, Huo C, Wang H, et al. Response pathways of superoxide dismutase and catalase under the regulation of triclocarban-triggered oxidative stress in Eisenia foetida: Comprehensive mechanism analysis based on cytotoxicity and binding model. Sci Total Environ. 2023;854:158821. [PubMed ID: 36116645]. https://doi.org/10.1016/j.scitotenv.2022.158821.
-
36.
Matic MM, Paunovic MG, Milosevic MD, Ognjanovic BI, Saicic ZS. Hematoprotective effects and antioxidant properties of beta-glucan and vitamin C against acetaminophen-induced toxicity: an experimental study in rats. Drug Chem Toxicol. 2021;44(3):302-9. [PubMed ID: 30880499]. https://doi.org/10.1080/01480545.2019.1587451.
-
37.
Fraga CG, Oteiza PI. Dietary flavonoids: Role of (-)-epicatechin and related procyanidins in cell signaling. Free Radic Biol Med. 2011;51(4):813-23. [PubMed ID: 21699974]. https://doi.org/10.1016/j.freeradbiomed.2011.06.002.
-
38.
Mendoza-Wilson AM, Castro-Arredondo SI, Balandran-Quintana RR. Computational study of the structure-free radical scavenging relationship of procyanidins. Food Chem. 2014;161:155-61. [PubMed ID: 24837934]. https://doi.org/10.1016/j.foodchem.2014.03.111.
-
39.
Wu H, Xie Y, Xu Y, Hu Z, Wan X, Huang H, et al. Protective effect of Epicatechin on APAP-induced acute liver injury of mice through anti-inflammation and apoptosis inhibition. Nat Prod Res. 2020;34(6):855-8. [PubMed ID: 30394110]. https://doi.org/10.1080/14786419.2018.1503261.
-
40.
Erlejman AG, Jaggers G, Fraga CG, Oteiza PI. TNFalpha-induced NF-kappaB activation and cell oxidant production are modulated by hexameric procyanidins in Caco-2 cells. Arch Biochem Biophys. 2008;476(2):186-95. [PubMed ID: 18275839]. https://doi.org/10.1016/j.abb.2008.01.024.
-
41.
Mazumder A, Sharma A, Azad MAK; Gajender. A Comprehensive Review of the Pharmacological Importance of Dietary Flavonoids as Hepatoprotective Agents. Evid Based Complement Alternat Med. 2023;2023:4139117. [PubMed ID: 37123086]. [PubMed Central ID: PMC10147524]. https://doi.org/10.1155/2023/4139117.
-
42.
Eldin DN, Fahim HI, Ahmed HY, Abdelgawad MA, Abourehab MAS, Ahmed OM. Preventive Effects of Mandarin Fruit Peel Hydroethanolic Extract, Hesperidin, and Quercetin on Acetaminophen-Induced Hepatonephrotoxicity in Wistar Rats. Oxid Med Cell Longev. 2022;2022:7065845. [PubMed ID: 36092164]. [PubMed Central ID: PMC9463012]. https://doi.org/10.1155/2022/7065845.
-
43.
Mohamed Kamel GA, Harahsheh E, Hussein S. Diacerein ameliorates acetaminophen hepatotoxicity in rats via inhibiting HMGB1/TLR4/NF-kappaB and upregulating PPAR-gamma signal. Mol Biol Rep. 2022;49(7):5863-74. [PubMed ID: 35366176]. [PubMed Central ID: PMC8975726]. https://doi.org/10.1007/s11033-022-07366-5.
-
44.
Oguz Cumaoglu M, Cumaoglu B, Tekin Y, Gunay N. Therapeutic effect of 6-shogaol on acetaminophen-induced hepatotoxicity in mice: an experimental study. Eur Rev Med Pharmacol Sci. 2022;26(20):7371-8. [PubMed ID: 36314307]. https://doi.org/10.26355/eurrev_202210_30006.